EBS - Emergent BioSolutions Inc.
52.20 0.00 (0.00%)
After hours: 4:59PM EDT
| Previous Close | 52.28 |
| Open | 52.52 |
| Bid | 50.00 x 400 |
| Ask | 54.99 x 100 |
| Day's Range | 52.07 - 53.06 |
| 52 Week Range | 28.85 - 55.91 |
| Volume | 199,996 |
| Avg. Volume | 370,203 |
| Market Cap | 2.6B |
| Beta | 1.27 |
| PE Ratio (TTM) | 30.60 |
| EPS (TTM) | 1.71 |
| Earnings Date | May 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.57 |
- Benzinga•yesterday
Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade
Specialty biopharma Emergent Biosolutions Inc (NYSE: EBS ) has seen its stock rise more than 40 percent over the past two years, and investors shouldn't expect to see such outsized returns going forward, ...
- GlobeNewswire•7 days ago
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
GAITHERSBURG, Md., April 19, 2018-- Emergent BioSolutions Inc. will host a conference call on Thursday, May 3, 2018 at 5:00 pm to discuss the financial results for the first quarter of 2018, recent business ...
Markit•10 days agoSee what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EBS. Over the last one-month, outflows of investor capital in ETFs holding EBS totaled $497 million.
- American City Business Journals•13 days ago
Emergent BioSolutions to enter 5 new countries with anthrax vaccine
The Gaithersburg-based biotech just received approval to introduce its anthrax vaccine in five European countries, a move that brings the possibility of a new and important revenue stream.
- GlobeNewswire•14 days ago
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
GAITHERSBURG, Md., April 12, 2018-- Emergent BioSolutions Inc. today announced the successful completion of the Mutual Recognition Procedure for market authorization of BioThrax ® in five Concerned Member ...
- Business Wire•14 days ago
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
Emergent BioSolutions Inc. today announced the successful completion of the Mutual Recognition Procedure for market authorisation of BioThrax® in five Concerned Member States within the European Union , including Italy, the Netherlands, Poland, the U.K., and France .
- Market Realist•17 days ago
Analyzing Roche’s Acquisition of Flatiron Health
In October 2017, Emergent BioSolutions (EBS) completed the acquisition of raxibacumab from GlaxoSmithKline (GSK). Raxibacumab is a fully human monoclonal antibody with approval from the FDA for treating inhalational anthrax. Raxibacumab has orphan drug designation in the US and was approved by the FDA in 2012.
- Zacks•20 days ago
Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
Let us look at the factors that have led to the increase in share price of Emergent (EBS).
- Market Realist•23 days ago
Why Amicus Therapeutics Stock Rose in the Week Ended March 29
A Look at Pharma's Gainers in the Week Ended March 29
- GlobeNewswire•24 days ago
New Research Coverage Highlights SITO Mobile, Emergent Biosolutions, Instructure, First Financial Bankshares, Jones Lang LaSalle, and QAD — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, April 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
GAITHERSBURG, Md., March 26, 2018-- Emergent BioSolutions Inc. today announced executive management changes that continue to align its organizational structure to its long-term strategy and to the achievement ...
- Zacks•last month
Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•last month
Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
GAITHERSBURG, Md., March 22, 2018-- Emergent BioSolutions Inc. today announced that its Board of Directors has authorized the company’ s management to implement a stock repurchase program for up to $50 ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of EBS earnings conference call or presentation 22-Feb-18 10:00pm GMT
Q4 2017 Emergent BioSolutions Inc Earnings Call
Markit•last monthSee what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
Emergent Biosolutions Inc NYSE:EBS
- American City Business Journals•2 months ago
One Gaithersburg biotech's latest marketing push: Selling doomsday kits on Amazon
For $50 and the cost of shipping on Amazon , you could get the same protection against chemical weapons that Gaithersburg's Emergent BioSolutions sells to protect soldiers on the ground. If you hit purchase, you would get what's called a reactive skin decontamination lotion kit. Inside are a sponge and specialized lotion cleared by the U.S. Food and Drug Administration to remove or neutralize such chemical warfare agents as sarin and mustard gas from the skin in a single step.
- GlobeNewswire•2 months ago
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
GAITHERSBURG, Md., Feb. 28, 2018-- Emergent BioSolutions Inc. today announced a contract award by the Centers for Disease Control and Prevention valued at $26 million over 12 months for the continued supply ...
- GlobeNewswire•2 months ago
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS GAITHERSBURG, Md. and LYON, France, February 26, 2018 - Emergent BioSolutions Inc. (NYSE: ...
- Motley Fool•2 months ago
Emergent BioSolutions Gets its Deals Done (and Expect More to Come)
Newly acquired products and contracts will help revenue growth accelerate in 2018.
- Zacks•2 months ago
Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.
- Associated Press•2 months ago
Emergent Biosolutions beats 4Q profit forecasts
The Gaithersburg, Maryland-based company said it had net income of 67 cents per share. Earnings, adjusted for non-recurring costs, were 74 cents per share. The results surpassed Wall Street expectations. ...
- ACCESSWIRE•2 months ago
Emergent BioSolutions Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Emergent BioSolutions Inc. (NYSE: EBS ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 5:00 PM Eastern ...
- Simply Wall St.•2 months ago
What You Must Know About Emergent BioSolutions Inc’s (NYSE:EBS) 12.20% ROE
Emergent BioSolutions Inc’s (NYSE:EBS) most recent return on equity was a substandard 12.20% relative to its industry performance of 16.59% over the past year. EBS’s results could indicate a relativelyRead More...
- ACCESSWIRE•2 months ago
Update in Lawsuit for Investors in NYSE: EBS Shares Against Emergent Biosolutions Inc. Announced by Shareholders Foundation
SAN DIEGO, CA / ACCESSWIRE / February 12, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of NYSE: EBS shares against Emergent Biosolutions Inc. over ...
Markit•3 months agoSee what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
Emergent Biosolutions Inc NYSE:EBS
